NCT04245839 2025-11-05
TRANSCEND FL
Celgene
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT03568461 2025-10-07
ELARA
Novartis
Phase 2 Completed
NCT04404660 2025-09-09
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Autolus Limited
Phase 1/2 Active not recruiting
NCT03575351 2025-08-03
TRANSFORM
Celgene
Phase 3 Completed
NCT03734016 2025-03-30
ALPINE
BeiGene
Phase 3 Completed
NCT02000427 2024-05-28
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Amgen
Phase 2 Completed
NCT02445248 2024-04-18
JULIET
Novartis
Phase 2 Completed
NCT02013167 2024-03-05
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Terminated
NCT02561988 2023-03-17
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Blueprint Medicines Corporation
Phase 1 Completed